moatshark My

All holdings

Royalty Pharma

RPRX

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
2
In their latest 13F (Q3 2026)
See who
Value held
$157m
Combined value at quarter end
Last quarter
2 bought
0 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q2 ’26 end
$56.07
+16.9% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+7.3%Q3 ’24
-9.8%Q4 ’24
+22.0%Q1 ’25
+15.7%Q2 ’25
-2.1%Q3 ’25
+9.5%Q4 ’25
+24.1%Q1 ’26
+16.9%Q2 ’26
Q3 ’24: +7.3%; Q4 ’24: -9.8%; Q1 ’25: +22.0%; Q2 ’25: +15.7%; Q3 ’25: -2.1%; Q4 ’25: +9.5%; Q1 ’26: +24.1%; Q2 ’26: +16.9%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

1Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
2Q3 ’25
2Q4 ’25
2Q1 ’26
2Q2 ’26
0Q3 ’26
Q4 ’23: 1; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 2; Q4 ’25: 2; Q1 ’26: 2; Q2 ’26: 2; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Royalty Pharma.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Royalty Pharma
Dorsey Asset Management8.8%$138m$138mAdded +7.9%4 qtrs
Horizon Kinetics0.2%$19.3m$19.3mAdded +1.2%22 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Royalty Pharma
Bought or soldFiling
5 Oct 2026Urist MarshallEVP, Research & Investments▼ Sold4,126$57.10$236kForm 4
28 Sep 2026Urist MarshallEVP, Research & Investments▼ Sold4,126$57.88$239kForm 4
22 Sep 2026Hite ChristopherEVP & Chairman, Partnering▼ Sold96,073$58.51$5.6mForm 4
22 Sep 2026Hite ChristopherEVP & Chairman, Partnering▼ Sold3,927$58.93$231kForm 4
18 Aug 2026Hite ChristopherEVP & Chairman, Partnering▼ Sold100,000$59.97$6.0mForm 4
13 Aug 2026Coyne Terrance P.EVP & CFO▼ Sold9,230$58.59$541kForm 4
13 Aug 2026Coyne Terrance P.EVP & CFO▼ Sold1,772$59.14$105kForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
United Kingdom
Financial year ends
31 December
Shares outstanding
388m at 10 Nov 2020
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$1.8bn2018
$1.8bn2019
$2.1bn2020
$2.3bn2021
$2.2bn2022
$2.4bn2023
$2.3bn2024
$2.4bn2025
2018: $1.8bn; 2019: $1.8bn; 2020: $2.1bn; 2021: $2.3bn; 2022: $2.2bn; 2023: $2.4bn; 2024: $2.3bn; 2025: $2.4bn
Royalty Pharma revenue and net income by year
YearRevenueNet income
2025$2.4bn$771m
2024$2.3bn$859m
2023$2.4bn$1.1bn
2022$2.2bn$42.8m
2021$2.3bn$620m
2020$2.1bn$975m
2019$1.8bn$2.3bn
2018$1.8bn$1.4bn

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Royalty Pharma, from their latest N-PORT filings.

Funds holding Royalty Pharma
Horizon Kinetics Inflation Beneficiaries ETFHorizon Kinetics1.2%$18.3m30 Jun 2026